Eli Lilly (United States)

本机构学者在这里署名、按本站篇数

合作机构同一篇文章里的其他机构

1. Georgetown University美国6
2. Pfizer (United States)美国5
3. AbbVie (United States)美国5
4. United States Food and Drug Administration美国5
5. Washington University in St. Louis美国4
6. Texas A&M University美国4
7. Sanofi (United States)美国3
8. European Medicines Agency荷兰3

按月发文

逐年被引

最新文献

1. 1
   DO Generations MAtter for Treatment of Outpatient Pyelonephritis With Cephalosporins in the Emergency Department? DOGMA-ED StudyAnnals of Emergency Medicine20260
2. 2
   A novel, widespread impurity in mass-compounded tirzepatide/B12 products: potential patient safety implicationsExpert Opinion on Drug Safety20262
3. 3
   Hepatic Effects, Potential Drug-Induced Liver Injury, and Other Liver Safety Considerations of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in the New Era of Expanding Non-oncology Indications: Literature Review and Expert ConsensusDrug Safety20253
4. 4
   The Impact of COVID-19 and COVID-19 Vaccination on Detection, Assessment, and Management of Suspected Acute Drug‐Induced Liver Injury Occurring during Clinical Trials: Consensus Recommendations from the IQ DILI InitiativeDrug Safety20253
5. 5
   CuratED: The emergency medicine pharmacotherapy literature of 2024American Journal of Emergency Medicine20252
6. 6
   A new small-scale dust cloud minimum ignition energy apparatusJournal of Loss Prevention in the Process Industries20252
7. 7
   Adapting the European Concerted Action on Congenital Anomalies and Twins ( EUROCAT ) Guide 1.5 for Use in Post‐Authorisation Safety Studies Using US DataPharmacoepidemiology and Drug Safety20250
8. 8
   Monitoring Pregnancies Exposed to Galcanezumab for Migraine in a United States Administrative Claims DatabasePharmacoepidemiology and Drug Safety20242
9. 9
   Treatment-emergent Candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with ixekizumab: an integrated safety analysis of 25 clinical studiesExpert Opinion on Drug Safety20243
10. 10
    Effectiveness of Baricitinib Risk Minimization Activities in Patients With Rheumatoid Arthritis—A Cohort Study in Four Nordic CountriesPharmacoepidemiology and Drug Safety20242

高被引文献

1. 1
   Recommendations for benefit–risk assessment methodologies and visual representationsPharmacoepidemiology and Drug Safety201678
2. 2
   Addressing unmeasured confounding in comparative observational researchPharmacoepidemiology and Drug Safety201863
3. 3
   Validation of an International Classification of Disease, 10th revision coding adaptation for the Charlson Comorbidity Index in United States healthcare claims dataPharmacoepidemiology and Drug Safety202147
4. 4
   Assessing the impact of unmeasured confounders for credible and reliable real‐world evidencePharmacoepidemiology and Drug Safety202046
5. 5
   Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic SteatohepatitisDrug Safety202041
6. 6
   Literature review of visual representation of the results of benefit–risk assessments of medicinal productsPharmacoepidemiology and Drug Safety201536
7. 7
   Drug-Induced Steatosis and Steatohepatitis: The Search for Novel Serum Biomarkers Among Potential Biomarkers for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic SteatohepatitisDrug Safety201932
8. 8
   Benefit–Risk Assessment, Communication, and Evaluation (BRACE) throughout the life cycle of therapeutic products: overall perspective and role of the pharmacoepidemiologistPharmacoepidemiology and Drug Safety201528
9. 9
   A long-term open-label safety study of galcanezumab in Japanese patients with migraineExpert Opinion on Drug Safety202128
10. 10
    Drug-Induced Liver Injury in the Elderly: Consensus Statements and Recommendations from the IQ-DILI InitiativeDrug Safety202427

主要发表期刊

研究主题